Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective

• Published in: The Annals of pharmacotherapy 2008-10, Vol.42 (10), p.1466-1474
• Main Authors: Khanderia, Ujjaini, Pop-Busui, Rodica, Eagle, Kim A
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Cardiology. Vascular system; Clinical Trials as Topic; Coronary heart disease; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Heart; Heart Failure - etiology; Heart Failure - prevention & control; Heart failure, cardiogenic pulmonary edema, cardiac enlargement; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Medical sciences; Meta-Analysis as Topic; Metformin - therapeutic use; Myocardial Infarction - etiology; Myocardial Infarction - prevention & control; Pharmacology. Drug treatments; Thiazolidinediones - adverse effects; Thiazolidinediones - therapeutic use
• ISSN: 1060-0280; 1542-6270
• DOI: 10.1345/aph.1K666

Objective: To examine the cardiovascular effects of thiazolidinediones (TZDs), discuss concerns regarding this drug class and its relation to heart failure (HF) and myocardial infarction (Ml), and address the clinical implications of HF and Ml. Data Sources: Literature was accessed through MEDLINE (1979-April 2008) using the search terms type 2 diabetes mellitus. thiazolidinediones. cardiovascular events, heart failure, myocardial infarction, and edema. Reviews, meta-analyses, clinical trials, observational studies (case-control, cohort), and descriptive studies (case reports, caso series) were included. Study Selection and Data Extraction: All articles that were written in English and identified from the data sources were reviewed. Data Synthesis: The American Diabetes Association recommends metformin as first-line therapy for type 2 diabetes, with the subsequent addition of a TZD, sulfonylurea, or insulin if the target is not met. Beyond glucose lowering, TZDs improvo various factors associated with cardiovascular risk. Whether the effects translate into beneficial cardiovascular outcomes is controversial. In PROactive (Prospective Pioglitazone Clinical Trial in Macrovascular Events), pioglitazone did not produce a significant reduction in the primary endpoint that included a composite of coronary and vascular deaths, but the secondary composite endpoint of all-cause mortality, Ml, or stroke was significantly reduced. Concerns related to HF have led to warnings in the labeling of TZDs. The drugs are contraindicated in patients with New York Head Association Class Ill or IV HF. Rosiglilazone, but not pioglitazone, is associated with an increased risk of myocardial ischemic events, although the absolute magnitude is extremely small. Conclusions: Although the glycemic efficacy of TZDs is comparable to that of metformin, ad verso effects and higher costs make TZDs less appealing for initial therapy. Among the TZDs. pioglitazone should be considered based on cardiovascular safety data. In combination with metformin, pioglitazone may be particularly beneficial for patients wilh diabetes and metabolic syndrome. For patients on rosigfitazone who are achieving glycemic goals and tolerating the therapy without apparent complications, rosiglitazone may be continued.